Strahinja Ninić

Investment Banking

Bryan, Garnier & Co, a leading pan-European investment bank focusing on growth companies, is delighted to announce that Strahinja Ninić has been appointed as Director in Investment Banking.

Strahinja joined Bryan, Garnier & Co in January as Director in the Energy Transition & Sustainability investment banking team, with the objective to further reinforce BG&Co expertise within the Alternative Proteins landscape, Food & AgTech and Sustainability by bringing industry perspective and a long transaction experience in the F&B space.

Prior to joining Bryan, Garnier & Co, Strahinja spent 9 years at Danone, a global food company and an industry leader in health and sustainability, as part of their corporate M&A and Waters strategy teams, based in Singapore and Paris. During his time at Danone, he gained extensive industry experience and a strong exposure to sustainability and innovation challenges in the food & beverage sector. Prior to Danone, Strahinja spent 5 years in the European M&A execution teams of BNP Paribas CIB.

With more than 60 private and public capital-raising and M&A transactions closed in 2020, Bryan, Garnier & Co benefits from longstanding leadership in the healthcare, technology, business services and environmental sectors in Europe. Over the past 36 months, Bryan, Garnier & Co has led more than 40 ECM transactions across nine countries, raising over EUR 2.5bn. Recent successes include the IPOs and/or follow-ons for HDF Energy (Euronext Paris), Mister SPEX (Deutsche Boerse), Carbios (Euronext Paris), Azelio (NASDAQ Stockholm), McPhy Energy (Euronext Paris), Linas Matkase (NASDAQ Stockholm), Heidelberg Pharma (Deutsche Börse), Swedish Stirling (NASDAQ Stockholm), Basilea (SIX) GenSight (Euronext Paris), and Valneva (NASDAQ / Euronext Paris).

Additional recent transactions include the acquisition of DL Software by TA Associates, the sale of smartTrade to leading software private equity investor Hg Capital, the take-private of ITSM player Easyvista by Eurazeo, capital for circular economy player asgoodasnew, the sale of Specim to Konica Minolta and the sale of BlueBee to Illumina. Over the years, Bryan, Garnier & Co has distinguished itself by backing some of the most disruptive companies in the domain of alternative proteins (Prolupin), green hydrogen (McPhy Energy), cannabis (Canopy Growth), 3D printing (Materialise), blockchain and cryptocurrencies (Bitfury Group), and mRNA biotech (Moderna and BioNTech).

About Bryan, Garnier & Co

Bryan, Garnier & Co is a European, full-service growth-focused independent investment banking partnership founded in 1996. The firm provides equity research, sales and trading, private and public capital raising as well as M&A services to growth companies and their investors. It focuses on key growth sectors of the economy including Technology, Healthcare, Consumer and Business Services. Bryan, Garnier & Co is a fully registered broker dealer authorized and regulated by the FCA in the UK, the AMF in Europe and the FINRA in the U.S. Bryan, Garnier & Co is headquartered in London, with additional offices in Paris, Munich, Stockholm, Oslo, Reykjavik and New York.

(www.bryangarnier.com)